{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-006981","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.698120+00:00","generated_at":"2026-05-15T23:26:44.371536+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rocket Pharma FY2025 net loss $223.1M; cash $188.9M; KRESLADI PDUFA March 28, 2026","bullets":["Net loss $223.1M ($2.01/shr) vs $258.7M ($2.73/shr) in FY2024; R&D spend down 17% to $142.0M.","Cash, cash equivalents & investments $188.9M; runway into Q2 2027; restructuring charges $3.2M.","Pivotal Phase 2 trial of RP-A501 (Danon disease) to resume 1H 2026 after FDA lifted clinical hold.","KRESLADI BLA resubmission accepted; PDUFA target action date March 28, 2026; eligible for PRV.","First patient dosing in Phase 1 RP-A701 (BAG3-DCM) expected mid-2026; Phase 1 trial startup ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-006981","json":"https://secwatch.observer/filing/0001140361-26-006981.json","markdown":"https://secwatch.observer/filing/0001140361-26-006981.md","text":"https://secwatch.observer/filing/0001140361-26-006981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/0001140361-26-006981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:26:44.371536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}